Finance

Lists
HUMA:NASDAQ
Humacyte Inc
0,60 US$
-0,10%
(-0,00060) 1D
0,60 US$
+0,67% (+0,0040)
Pre-market
Closed: 3 სექ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HUMA...
Open
0,61 US$
High
0,61 US$
Low
0,58 US$
Mkt. cap
164,63 მლნ.
Avg. vol.
7,95 მლნ.
Volume
18,69 ათ.
52-wk high
2,55 US$
52-wk low
0,53 US$
EPS
-0,49 US$
Beta
2,45
Shares outstanding
277,80 მლნ.
No. of employees
184
Open
0,61 US$
High
0,61 US$
Low
0,58 US$
Mkt. cap
164,63 მლნ.
Avg. vol.
7,95 მლნ.
Volume
18,69 ათ.
52-wk high
2,55 US$
52-wk low
0,53 US$
EPS
-0,49 US$
Beta
2,45
Shares outstanding
277,80 მლნ.
No. of employees
184
News stories
From web sources and news partners
About Humacyte Inc
CEOლორა ნიკლეისონი
Employees184
Founded1 იან. 2004
Headquarters-
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to HUMA in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for HUMA in the last 3 months.
Highest
Current 0,60 US$
4,00 US$ (+571,14%)
Average
2,06 US$ (+245,64%)
Lowest
1,00 US$ (+67,79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Josh Jennings
TD Cowen
Buy
Maintained
1,25 US$
+109,7%
08/19/2026
Allison Bratzel
Piper Sandler
Hold
Maintained
1,00 US$
+67,8%
08/17/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
4,00 US$
+571,1%
08/13/2026
Ryan Zimmerman
BTIG
Buy
Maintained
2,00 US$
+235,6%
07/28/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
2,00 US$
+235,6%
06/01/2026
Matt Miksic
Barclays
Buy
Reiterated
1,50 US$
+151,7%
05/13/2026
Last report
12 აგვ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,16 US$ / -0,10 US$
-54,84%miss
Revenue / Est. (USD)
406,00 ათ. / 1,11 მლნ.
-63,52%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
753,00 ათ.
467,00 ათ.
495,00 ათ.
406,00 ათ.
Cost of goods sold
17,53 მლნ.
23,69 მლნ.
20,90 მლნ.
19,38 მლნ.
Cost of revenue
17,53 მლნ.
23,69 მლნ.
20,90 მლნ.
19,38 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,61 მლნ.
7,62 მლნ.
7,83 მლნ.
8,03 მლნ.
Operating expense
7,61 მლნ.
7,62 მლნ.
7,83 მლნ.
8,03 მლნ.
Total operating expenses
25,14 მლნ.
31,30 მლნ.
28,73 მლნ.
27,40 მლნ.
Operating income
-24,39 მლნ.
-30,84 მლნ.
-28,24 მლნ.
-27,00 მლნ.
Other non operating income
4,01 მლნ.
20,57 მლნ.
8,52 მლნ.
-5,16 მლნ.
EBT including unusual items
-17,51 მლნ.
-24,80 მლნ.
-17,62 მლნ.
-36,80 მლნ.
EBT excluding unusual items
-22,40 მლნ.
-12,85 მლნ.
-21,65 მლნ.
-34,08 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17,51 მლნ.
-24,80 მლნ.
-17,62 მლნ.
-36,80 მლნ.
Net profit margin
-2 325,37%
-5 311,35%
-3 559,39%
-9 064,53%
Earnings per share
-0,11
-0,13
-0,09
-0,16
Interest and investment income
590,00 ათ.
503,00 ათ.
330,00 ათ.
388,00 ათ.
Interest expense
-2,61 მლნ.
-3,09 მლნ.
-2,27 მლნ.
-2,32 მლნ.
Net interest expenses
-2,02 მლნ.
-2,59 მლნ.
-1,94 მლნ.
-1,93 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,52 მლნ.
-29,05 მლნ.
-26,44 მლნ.
-25,21 მლნ.
Gain or loss from assets sale
-
5,00 ათ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები